Quality of life in patients with uveitis: data from the ULISSE study (Uveitis: cLInical and medico-economic evaluation of a Standardised Strategy for the Etiological diagnosis).


Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
07 2021
Historique:
received: 13 02 2020
accepted: 03 07 2020
revised: 12 05 2020
pubmed: 28 7 2020
medline: 25 9 2021
entrez: 26 7 2020
Statut: ppublish

Résumé

To assess vision-related (VR-QOL) and health-related quality of life (HR-QOL) in a large series of patients with de novo uveitis at baseline and 6-month follow-up. Non-inferiority, prospective, multicentre, cluster randomised controlled trial registered under the Unique Identifier: NCT01162070. VR-QOL and HR-QOL were assessed by the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) and the Medical Outcomes Study 36-item Short Form Survey (SF-36). At inclusion, 466 patients completed the VFQ-25. The mean composite score was 80.0 (±16.7). In multivariate analysis, higher age, female sex and insidious onset were significantly associated with lower QOL. At 6 months, 138 patients completed the VFQ-25, with a significantly higher mean composite score of 82.6 (±16.7). SF-36 mental component was 42.9 (±11.3) and physical component was 47.2 (±8.5) at inclusion (n=425). HR-QOL improvement at 6 months was not clinically significant. QOL seems relatively well preserved in this cohort; only VR-QOL improved significantly at 6 months, especially in patients with low initial visual acuity.

Identifiants

pubmed: 32709757
pii: bjophthalmol-2020-315862
doi: 10.1136/bjophthalmol-2020-315862
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

935-940

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Pierre-Jean Bertrand (PJ)

Internal Medicine, Hospices Civils De Lyon, Lyon, France pascal.seve@chu-lyon.fr.

Yvan Jamilloux (Y)

Internal Medicine, Hopital De La Croix-Rousse,Lyon, France.

Laurent Kodjikian (L)

Ophthalmology, Croix Rousse University Hospital, Hospices Civils De Lyon, Lyon, France.

Marie-Helene Errera (MH)

Department of Ophthalmology, Quinze-Vingts Hospital, Paris, France.

Laurent Perard (L)

Internal Medicine, Edouart Herriot University Hospital, Hospices Civils De Lyon, Lyon, France.

Gregory Pugnet (G)

Department of Internal Medicine, Purpan University Hospital, Toulouse, France.

Nathalie Tieulie (N)

Deparment of Rheumatology, Archet Hospital, Nice, France.

Marc Andre (M)

Médecine Interne, Hopital Gabriel Montpied, Clermont-Ferrand,France.

Philip Bielefeld (P)

Médecine Interne, Centre Hospitalier Universitaire De Dijon, Dijon, France.

Alain M Bron (AM)

Ophthalmology, University Hospital, Dijon, France.

Evelyne Decullier (E)

Pole IMER Lyon, Hospices Civils de Lyon, Lyon, France.

Sylvie Bin (S)

Pole IMER Lyon, Hospices Civils de Lyon, Lyon, France.

Pascal Seve (P)

Internal Medicine, Hospices Civils De Lyon, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH